Albany Molecular Research, Inc. (NASDAQ:AMRI), announced that it has completed the acquisition of Oso Biopharmaceuticals Manufacturing, a former portfolio company of Altaris Capital Partners, LLC. The transaction is consistent with AMRI’s strategy to be the preeminent supplier of custom and complex drug product development and manufacturing services to the pharmaceutical industry. Albany Molecular Research, Inc. (NASDAQ:AMRI), net profit margin is 3.90% and weekly performance is 8.46%. On last trading day company shares ended up $21.28. Analysts mean target price for the company is $17.00. Albany Molecular Research, Inc. (NASDAQ:AMRI), distance from 50-day simple moving average (SMA50) is 24.92%.
Tower Group International, Ltd. (NASDAQ:TWGP), the insurer that agreed to bebought by ACP Re Ltd., plunged to a record low amid doubts over whether the deal will be completed. Tower Group International, Ltd. (NASDAQ:TWGP), advanced 8.33% in last trading session and ended the day on $1.95. TWGP, return on assets is -19.50%. Tower Group International, Ltd. (NASDAQ:TWGP), quarterly performance is -27.24%.
Regeneron Pharmaceuticals Inc (NASDAQ:REGN), major shareholder Sanofi acquired 262,400 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Monday, June 30th. The stock was purchased at an average price of $281.17 per share, for a total transaction of $73,779,008.00. Regeneron Pharmaceuticals Inc (NASDAQ:REGN), shares moved up 7.41% in last trading session and was closed at $303.39, while trading in range of $285.06 – 304.41. Regeneron Pharmaceuticals Inc (NASDAQ:REGN), year to date (YTD) performance is 10.23%.
CTI BioPharma Corp (NASDAQ:CTIC), announced that it has completed recruitment in the PERSIST-1 pivotal Phase 3 clinical trial of pacritinib, a novel oral JAK2/FLT3 inhibitor that is being evaluated for the treatment of myelofibrosis. Under the development and commercialization agreement for pacritinib with Baxter International, Inc. (Baxter), CTI expects to receive a $20 million development milestone payment in connection with the first treatment dosing of the last patient enrolled in PERSIST-1. CTI expects to achieve this milestone and receive payment by mid-third quarter 2014. CTI BioPharma Corp (NASDAQ:CTIC), ended the last trading day at $3.09. Company weekly volatility is calculated as 3.19% and price to cash ratio as 9.15. CTI BioPharma Corp (NASDAQ:CTIC), showed a negative weekly performance of 7.29%.
Galena Biopharma Inc (NASDAQ:GALE)‘s stock had its “buy” rating reiterated by Noble Financial in a research note issued on Wednesday, American Banking and Market News reports. Galena Biopharma Inc (NASDAQ:GALE), net profit margin is 7.26% and weekly performance is 6.88%. On last trading day company shares ended up $3.25. Galena Biopharma Inc (NASDAQ:GALE), distance from 50-day simple moving average (SMA50) is 27.90%.